Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).

Veröffentlicht vonadmin

Moehler, M; Maderer, A; Thuss-Patience, PC; Brenner, B; Meiler, J; Ettrich, TJ; Hofheinz, RD; Al-Batran, SE; Vogel, A; Mueller, L; Lutz, MP; Lordick, F; Alsina, M; Borchert, K; Greil, R; Eisterer, W; Schad, A; Slotta-Huspenina, J; Van Cutsem, E; Lorenzen, S

View this publication in the PUBMED database